SCM
ABOS icon

Sterling Capital Management’s Acumen Pharmaceuticals ABOS Stock Holding History

Sterling Capital Management’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-685
Closed -$754 – 3264
2025
Q1 		$754 Sell
685
-740
-52% -$1.06K ﹤0.01% 2894
2024
Q4 		$2.45K Buy
1,425
+1,292
+971% +$3.11K ﹤0.01% 2726
2024
Q3 		$330 Buy
+133
New +$361 ﹤0.01% 3010

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Sterling Capital Management's ABOS Position: Q2 2025 in Review

Sterling Capital Management sold out of Acumen Pharmaceuticals (ABOS) in Q2 2025, closing a stake of 685 shares — an estimated $754 sold.

Sterling Capital Management first reported a position in ABOS in Q3 2024 and held it in 3 quarters. The position peaked at $2.45K in Q4 2024. 71 funds tracked by Wall St. Rank hold ABOS as of Q2 2025.

  • Sterling Capital Management reported no remaining Acumen Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Sterling Capital Management sold 685 Acumen Pharmaceuticals shares in Q2 2025, an estimated $754.
  • Sterling Capital Management first reported a position in Acumen Pharmaceuticals in Q3 2024 and held it in 3 quarters.
  • Sterling Capital Management's Acumen Pharmaceuticals position peaked at $2.45K in Q4 2024.
  • 71 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2025.

Based on Sterling Capital Management's 13F filing for Q2 2025, filed 6 Aug 2025.